178 related articles for article (PubMed ID: 29622797)
1. Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.
Newman JH; Augeri DJ; NeMoyer R; Malhotra J; Langenfeld E; Chesson CB; Dobias NS; Lee MJ; Tarabichi S; Jhawar SR; Bommareddy PK; Marshall S; Sadimin ET; Kerrigan JE; Goedken M; Minerowicz C; Jabbour SK; Li S; Carayannopolous MO; Zloza A; Langenfeld J
Oncogene; 2018 Jul; 37(27):3672-3685. PubMed ID: 29622797
[TBL] [Abstract][Full Text] [Related]
2. DMH1, a small molecule inhibitor of BMP type i receptors, suppresses growth and invasion of lung cancer.
Hao J; Lee R; Chang A; Fan J; Labib C; Parsa C; Orlando R; Andresen B; Huang Y
PLoS One; 2014; 9(6):e90748. PubMed ID: 24603907
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death.
Augeri DJ; Langenfeld E; Castle M; Gilleran JA; Langenfeld J
Mol Cancer; 2016 Apr; 15():27. PubMed ID: 27048361
[TBL] [Abstract][Full Text] [Related]
4. Small molecule antagonist of the bone morphogenetic protein type I receptors suppresses growth and expression of Id1 and Id3 in lung cancer cells expressing Oct4 or nestin.
Langenfeld E; Deen M; Zachariah E; Langenfeld J
Mol Cancer; 2013 Oct; 12(1):129. PubMed ID: 24160469
[TBL] [Abstract][Full Text] [Related]
5. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines.
Langenfeld E; Hong CC; Lanke G; Langenfeld J
PLoS One; 2013; 8(4):e61256. PubMed ID: 23593444
[TBL] [Abstract][Full Text] [Related]
7. Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells.
Mondal A; NeMoyer R; Vora M; Napoli L; Syed Z; Langenfeld E; Jia D; Peng Y; Gilleran J; Roberge J; Rongo C; Jabbour SK; Langenfeld J
Cell Commun Signal; 2021 Sep; 19(1):97. PubMed ID: 34563224
[TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic protein receptor inhibitors suppress the growth of glioblastoma cells.
Kaye J; Mondal A; Foty R; Jia D; Langenfeld J
Mol Cell Biochem; 2022 May; 477(5):1583-1595. PubMed ID: 35192123
[TBL] [Abstract][Full Text] [Related]
9. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
10. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
Gooding S; Olechnowicz SWZ; Morris EV; Armitage AE; Arezes J; Frost J; Repapi E; Edwards JR; Ashley N; Waugh C; Gray N; Martinez-Hackert E; Lim PJ; Pasricha SR; Knowles H; Mead AJ; Ramasamy K; Drakesmith H; Edwards CM
Nat Commun; 2019 Oct; 10(1):4533. PubMed ID: 31586071
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H
Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898
[TBL] [Abstract][Full Text] [Related]
13. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
14. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
[TBL] [Abstract][Full Text] [Related]
15. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY
Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer.
Song M; Ping Y; Zhang K; Yang L; Li F; Zhang C; Cheng S; Yue D; Maimela NR; Qu J; Liu S; Sun T; Li Z; Xia J; Zhang B; Wang L; Zhang Y
Cancer Res; 2019 Jul; 79(14):3737-3748. PubMed ID: 31085700
[TBL] [Abstract][Full Text] [Related]
18. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.
Futami T; Okada H; Kihara R; Kawase T; Nakayama A; Suzuki T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Mol Cancer Ther; 2017 Jan; 16(1):68-75. PubMed ID: 27837028
[TBL] [Abstract][Full Text] [Related]
19. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
[TBL] [Abstract][Full Text] [Related]
20. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
